Regenxbio Inc
$ 9.19
-1.82%
16 Apr - close price
- Market Cap 483,137,000 USD
- Current Price $ 9.19
- High / Low $ 9.42 / 9.04
- Stock P/E N/A
- Book Value 2.02
- EPS -3.76
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -1.07 %
- 52 Week High 16.19
- 52 Week Low 5.85
About
REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies intended to affect disease. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$27.82
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-06 | 2024-08-01 | 2024-05-08 | 2024-02-27 | 2023-11-08 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -1.3 | -1.2 | -1.38 | 0.12 | -1.01 | -1.17 | -1.05 | -1.33 | -1.43 | -1.41 | -1.66 | -1.53 |
| Estimated EPS | -0.7194 | -1.3 | -0.94 | 0.4856 | -1.0844 | -1.12 | -1.29 | -1.26 | -1.27 | -1.52 | -1.38 | -1.54 |
| Surprise | -0.5806 | 0.1 | -0.44 | -0.3656 | 0.0744 | -0.05 | 0.24 | -0.07 | -0.16 | 0.11 | -0.28 | 0.01 |
| Surprise Percentage | -80.7061% | 7.6923% | -46.8085% | -75.2883% | 6.8609% | -4.4643% | 18.6047% | -5.5556% | -12.5984% | 7.2368% | -20.2899% | 0.6494% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGNX
2026-04-15 21:10:10
This article announces an ARS SEC filing by REGENXBIO Inc. (RGNX) dated April 14, 2026, accessible as a PDF document. It provides an overview of the filing's low impact and neutral sentiment, along with recent news and other SEC filings related to the company. The company's stock data, including market cap and industry, are also listed.
2026-04-15 18:41:29
The Lifshitz Law Firm is conducting investigations into potential securities law violations and breaches of fiduciary duties at PayPal Holdings, Inc., Enphase Energy, Inc., and REGENXBIO Inc. These investigations could result in shareholder lawsuits and regulatory actions, potentially impacting the companies' stock and public reputation. The firm announced these investigations on April 15, 2026, examining various issues to determine if actionable claims exist on behalf of shareholders.
2026-04-15 09:41:29
Bronstein, Gewirtz & Grossman, LLC reminds investors of REGENXBIO Inc. (NASDAQ:RGNX) about the ongoing class action lawsuit. The lawsuit alleges that REGENXBIO made misleading statements regarding its gene therapy RGX‑111 for Hurler syndrome, overstating its efficacy and safety. Investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, have until April 14, 2026, to request to be appointed lead plaintiff.
2026-04-14 20:40:02
REGENXBIO Inc. (RGNX) has released details for its 2026 annual stockholders' meeting, where key agenda items include the election of three Class II directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and an advisory vote on 2025 executive compensation. Notably, stockholders will also vote on two separate stock option exchange programs for both non-executive and executive employees to address underwater options, aiming to incentivize and retain talent. The proxy statement also highlights the company's clinical progress in gene therapy and a strong financial position, ending 2025 with $240.9 million in cash.
2026-04-14 15:39:06
The Rosen Law Firm has announced a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges REGENXBIO misled investors about the efficacy and safety of its product candidate RGX-111, causing investors to suffer losses. Stockholders with significant losses are urged to contact the firm by the April 14, 2026, deadline to potentially serve as lead plaintiff.
2026-04-14 15:39:06
Rosen Law Firm has announced a class action lawsuit against REGENXBIO, Inc. (NASDAQ: RGNX) on behalf of investors who purchased securities between February 9, 2022, and January 27, 2026. The lawsuit alleges that REGENXBIO misled investors about the efficacy and safety of its product candidate RGX-111, a gene therapy for Hurler syndrome. Stockholders with significant losses are urged to contact the firm by the April 14, 2026, lead plaintiff deadline to learn about their rights.
